Comera Life Sciences Expands Woburn Operations
04 Ottobre 2022 - 4:30PM
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences
company developing a new generation of bio-innovative biologic
medicines to improve patient access, safety, and convenience, today
announced the expansion of its Woburn, Mass. operations with a
ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass.,
spans over 5,000 square feet and includes an expanded laboratory
space for R&D activities as well as new executive offices.
The Comera team was joined by state and local
officials and members of the biotech industry, including
Massachusetts State Senator Cindy F. Friedman, Massachusetts State
Representative Richard M. Haggerty, Woburn Mayor Scott Galvin and
Massachusetts Biotechnology Council (MassBio) President and COO
Kendalle Burlin O’Connell. Comera currently has 12 employees. The
increased footprint will allow the company to double its workforce
in the coming years.
“The expansion of our headquarters in Woburn is
a milestone achievement as we continue to advance our internal
pipeline and collaborations with some of the largest
biopharmaceutical companies,” said Jeffrey Hackman, Chairman and
CEO of Comera. “This expansion is another step forward in
supporting our continued growth as we execute on our long-term
strategy to transform the lives of patients.”
Comera is developing a portfolio of proprietary
injectable therapeutics – called subcutaneous (SQ) therapeutics –
with the goal of making it possible for patients to administer
medications that historically have been administered only by
intravenous (IV) infusion. The company applies its team’s deep
knowledge of formulation science and technology to transform
essential biologic medicines from IV to SQ forms, which has the
potential to spare patients long trips to a hospital or infusion
center, where they may stay for hours to receive treatment.
“Access to necessary and lifesaving medications
is a huge barrier for many in our commonwealth,” said Friedman,
Senate Chair of the Joint Committee on Health Care Financing. “The
work of Comera Life Sciences seeks to directly address this barrier
by providing a more convenient and equitable way to access these
medications. I am pleased to have Comera continue this important
work in Woburn and Massachusetts.”
“I am thrilled to see Comera expanding its
footprint here and continuing to develop biologic medicines in our
city,” said Haggerty. “Life science firms see the benefits of
locating and growing in Woburn, and I look forward to seeing what
the future holds for Comera as the firm grows and increases its
workforce in our community.”
“As the life sciences industry in Massachusetts continues to
regionalize to places outside of Boston and Cambridge like Woburn,
it makes careers available to new pools of talent and brings
economic development to new cities and towns that are BioReady,”
said Burlin O’Connell. “I am pleased to celebrate with our MassBio
member Comera as they reach this milestone in their growth and
continue to seek to deliver comfort and accessibility to
patients.”
The expansion is the latest milestone achieved
by Comera this year. The company made its debut as a publicly
traded company on the Nasdaq index in May.
About Comera Life Sciences
Leading a compassionate new era in medicine,
Comera Life Sciences is applying a deep knowledge of formulation
science and technology to transform essential biologic medicines
from intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences,
visit comeralifesciences.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the federal securities laws
including statements regarding our ability to execute on our
business strategy and our ability to access the $15 million in
proceeds under the purchase agreement, or to exercise the option
for an additional $15 million, due to the limitations contained in
the purchase agreement. These forward-looking statements generally
are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
document, including, but not limited to: risks that the limitations
in the purchase agreement will limit our sales and/or prevent us to
exercise our option or that we will need to seek stockholder
approval, which we may not be able to obtain, to remove such
limitations; that the recently completed business combination
disrupts the Company’s current plans and ability to retain its
employees; the Company’s ability to maintain the listing of its
securities on the Nasdaq Capital Market; the effect of the COVID-19
pandemic on the Company’s business; the price of the Company’s
securities may be volatile due to a variety of factors, including
changes in the competitive and highly regulated industries in which
the Company plans to operate, variations in performance across
competitors, changes in laws and regulations affecting the
Company’s business and changes in the capital structure; the
ability to implement business plans, forecasts, and other
expectations and identify and realize additional opportunities; the
risk of downturns and the possibility of rapid change in the highly
competitive industry in which the Company operates; the risk that
the Company and its current and future collaborators are unable to
successfully develop and commercialize the Company’s products or
services, or experience significant delays in doing so; the risk
that we will be unable to continue to attract and retain
third-party collaborators, including collaboration partners and
licensors; the risk that the Company may never achieve or sustain
profitability; the risk that the Company will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all; the risk that the Company
experiences difficulties in managing its growth and expanding
operations; the risk that third-party suppliers and manufacturers
are not able to fully and timely meet their obligations; the risk
that the Company is unable to secure or protect its intellectual
property; the risk that the Company is unable to secure regulatory
approval for its product candidates; general economic conditions;
and other risks and uncertainties indicated in the Current Report
on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors”
and in other filings that have been made or will be made with the
SEC. The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Comera’s
Current Report on Form 8-K filed with the SEC on May 25, 2022 and
other documents filed by Comera from time to time with the SEC.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Comera assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Comera can
give no assurance that it will achieve its expectations.
Contacts
Comera Investor:John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press:Greg TurnerBall Consulting Group,
LLCgreg@ballcg.com617-243-9950Karen Chase ICR
WestwickeKaren.Chase@westwicke.com
Grafico Azioni Comera Life Sciences (NASDAQ:CMRA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Comera Life Sciences (NASDAQ:CMRA)
Storico
Da Giu 2023 a Giu 2024